AAO 2006

Article

All the news from the 2006 meeting of the American Academy of Ophthalmology, held November 11–14 2006 in Las Vegas, NV, US

All the news from the 2006 meeting of the American Academy of Ophthalmology, held November 11–14 2006 in Las Vegas, NV, US.

 

Disclaimer:This information has been independently developed and provided by the editors of Ophthalmology Times Europe.

The sponsors do not endorse and are not responsible for the accuracy of the content or for practices or standards of non-sponsor sources.

These articles may discuss regimens that have not been approved by the appropriate regulatory bodies. For full prescribing information including indications, contraindications, warnings, precautions, and adverse experiences please see the appropriate manufacturer's product circular.

 

Evaluating the risk and progression of glaucoma: easier said than doneMore prospective studies are needed to evaluate the role of diurnal and long-term intraocular pressure (IOP) function in glaucoma development and progression, according to Felipe A. Medeiros, MD, PhD, assistant professor of ophthalmology, University of California at San Diego, USA, speaking at the glaucoma subspecialty session. 

Debating the importance of blue light filteringBlue light filtering intraocular lenses (IOLs) provide protection against potential blue light toxicity without significantly affecting clinical functioning of recipients, said James D. McCulley, MD, during a spotlight session on pseudophakic IOLs. 

Debating the importance of blue light filteringBlue light filtering intraocular lenses (IOLs) provide protection against potential blue light toxicity without significantly affecting clinical functioning of recipients, said James D. McCulley, MD, during a spotlight session on pseudophakic IOLs. 

Oral therapy the right choice for infectionsOral antiviral medications offer an effective, more convenient option compared with topical antiviral therapy for patients with acute infectious ulcers associated with herpes simplex keratitis. Oral treatment increases the likelihood of therapy adherence, according to Deborah P. Langston, MD, FACS, speaking at the eye infection symposium. 

CK effects not permanentConductive keratoplasty (CK) corrects mild-to-moderate hyperopia, but the results may not be permanent, according to Jason Erlich, MD, of Stanford University School of Medicine, USA. 

Pellucid: a hidden dangerClinicians should learn how to identify pellucid and screen patients for it prior to refractive surgery, according to Yaron Rabinowitz, MD, director of ophthalmology research, Cedars Sinai Medical Center, Los Angeles, USA. 

Dry eye: steps to successAllan Slomovic, University of Toronto, Canada, speaking at a continuing education symposium on dry eye diagnosis and management, outlined a five-step diagnostic algorithm for dry eye. 

Monovision ideal for most presbyopesSurgical monovision is an attractive option for presbyopes seeking refractive surgery and wanting freedom from glasses and contact lenses, according to Mark Mannis, MD, University of California, USA. 

Lucentis in DME: so far so goodRanibizumab (Lucentis; Novartis) is an effective treatment for diabetic macular oedema (DME), according to Peter Campochiaro, MD, from the Department of Ophthalmology, Wilmer Eye Institute, USA, speaking at the Retina Subspecialty Day. 

 

Disclaimer:This information has been independently developed and provided by the editors of Ophthalmology Times Europe.

The sponsors do not endorse and are not responsible for the accuracy of the content or for practices or standards of non-sponsor sources.

These articles may discuss regimens that have not been approved by the appropriate regulatory bodies. For full prescribing information including indications, contraindications, warnings, precautions, and adverse experiences please see the appropriate manufacturer's product circular.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.